The Target Is Known. The Precision Is the Problem.

Alterome is designing small-molecule cancer therapies to hit specific disease-driving mutations while sparing the closely related biology healthy cells need.

Precision cancer treatment has to answer three questions: What is driving the tumor? Can a medicine reach it? And can it do so without disabling machinery that healthy cells need?

Genomic testing has made the first question easier. The other two remain stubbornly hard. Cancer drivers including KRAS and AKT have been studied for decades, yet knowing the culprit is not the same as making a useful drug. A medicine that hits too broadly can cause side effects that limit dosing. One that works only against a narrow mutation or a single protein state may leave many patients uncovered.

Alterome is building into that gap. The company is developing alteration-specific small molecules that aim to inhibit the disease-driving version of a protein while sparing closely related normal biology. Our partner Uwe Schoenbeck led Canaan's participation in Alterome's $132 million Series B and joined its board. For us, Alterome represents a more exacting chapter of precision oncology: not simply matching a drug to a genetic label, but engineering the drug around the precise alteration that makes the cancer dangerous.

For years, the practical way to block a cancer pathway was often to inhibit a whole family of proteins. That bargain made sense. Protein structures can be difficult to drug, and medicinal chemists worked with the binding sites available to them.

But the same proteins that help tumors grow may also regulate essential functions in healthy tissue. AKT is a good example. Older approaches have generally inhibited several forms of AKT at once. That can suppress cancer signaling, but it can also interfere with normal metabolism and other processes, narrowing the margin between an effective dose and an intolerable one.

KRAS presents a different version of the problem. It was long considered undruggable because its shape offered few obvious places for a small molecule to bind. The first mutation-specific medicines proved KRAS could be reached. They also exposed the next challenge: covering more mutations and protein states without unnecessarily inhibiting related proteins.

This is why Alterome's timing matters. Genomics can identify the alterations driving a tumor. Structural biology can reveal how those proteins behave. Computational and physics-based design can model how a medicine might bind, while medicinal chemists can turn that design into a molecule that works in the body.

Alterome brings those disciplines together. Rather than searching broadly for unproven biology, the team starts with clinically validated cancer drivers and asks whether a more carefully designed molecule can change the therapeutic tradeoff.

Its two lead programs make that strategy concrete. Tanerasertib, also called ALTA2618, is designed to target the AKT1 E17K mutation while sparing wild-type AKT1 and avoiding inhibition of AKT2. ALTA3263 is designed to inhibit a broad range of KRAS mutations in both the protein's ON and OFF states, while sparing the related proteins HRAS and NRAS. Both programs are in Phase 1/1b studies evaluating safety, tolerability, pharmacokinetics, and preliminary activity. These are investigational medicines, and their clinical benefit has not been established.

What makes Alterome distinctive is the sequence of its thinking. It begins with biology whose importance is already clear, then applies precision to the part that has constrained treatment: the drug itself.

That choice reduces one kind of uncertainty while taking on a hard engineering problem: understand the mutant protein, bind the intended form, spare related biology, and preserve the properties required for an oral medicine. In four years, Alterome moved two internally discovered candidates from idea to clinical testing. That is not evidence of efficacy, but it shows the company's integrated approach can produce candidates ready to be tested in people.

When Uwe led our investment, Alterome aligned closely with a focus we had articulated for Canaan's healthcare work: genetically defined precision approaches aimed at meaningful clinical outcomes. Alterome made that idea tangible. The company was not asking the market to believe in an unknown cancer driver. It was asking whether better design could turn deeply validated biology into more selective medicines.

What stood out to us was the combination of ambition and discipline. Alterome chose targets of enormous importance, but did not treat scale as an excuse for breadth. Co-founders Eric Murphy, an oncology drug-discovery veteran, and physician-scientist Ryan Corcoran built around the idea that the right unit of precision is not only the gene. It is the alteration, protein state, and biological context a medicine must address.

For a patient, precision is not a scientific adjective. It shapes whether a medicine can be dosed strongly enough, tolerated long enough, and used across the mutations that appear in cancer. The difference between hitting a protein family and the disease-driving alteration can separate a promising mechanism from a practical treatment.

The question Alterome is asking is not simply whether KRAS or AKT can be inhibited. It is whether drug design can become precise enough to separate the biology that drives cancer from the biology a person needs to live.

If Alterome succeeds, the larger shift will be that precision oncology moved one level deeper, from identifying the genetic address of a cancer to designing medicines that fit it with less compromise. That is the future we saw in the company: known targets no longer accepted as unreachable, and greater precision widening what treatment can make possible.